These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 32694058

  • 1. Mid-Term Outcomes After Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
    Okada M, Tomosugi T, Futamura K, Hiramitsu T, Goto N, Narumi S, Takeda A, Watarai Y.
    Transplant Proc; 2020 Dec; 52(10):3051-3057. PubMed ID: 32694058
    [Abstract] [Full Text] [Related]

  • 2. Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.
    Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, Jouven X, Glotz D, Legendre C, Lefaucheur C, Halloran PF.
    J Am Soc Nephrol; 2017 Jun; 28(6):1912-1923. PubMed ID: 28255002
    [Abstract] [Full Text] [Related]

  • 3. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
    Parajuli S, Joachim E, Alagusundaramoorthy S, Blazel J, Aziz F, Garg N, Muth B, Mohamed M, Mandelbrot D, Zhong W, Djamali A.
    Transplantation; 2019 Aug; 103(8):1722-1729. PubMed ID: 30507740
    [Abstract] [Full Text] [Related]

  • 4. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.
    Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Jouven X, Delahousse M, Kamar N, Lefaucheur C.
    J Am Soc Nephrol; 2018 Feb; 29(2):606-619. PubMed ID: 29255058
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M, Nocera A, Tagliamacco A, Basso S, Innocente A, Fontana I, Magnasco A, Trivelli A, Klersy C, Gurrado A, Ramondetta M, Boghen S, Catenacci L, Verrina E, Garibotto G, Ghiggeri GM, Cardillo M, Ginevri F, Comoli P.
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
    Touzot M, Couvrat-Desvergnes G, Castagnet S, Cesbron A, Renaudin K, Cantarovich D, Giral M.
    Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
    [Abstract] [Full Text] [Related]

  • 9. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E, Eskandary F, Kozakowski N, Bond G, Kikić Ž, Yoo D, Rasoul-Rockenschaub S, Oberbauer R, Böhmig GA.
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
    Loupy A, Vernerey D, Tinel C, Aubert O, Duong van Huyen JP, Rabant M, Verine J, Nochy D, Empana JP, Martinez F, Glotz D, Jouven X, Legendre C, Lefaucheur C.
    J Am Soc Nephrol; 2015 Jul; 26(7):1721-31. PubMed ID: 25556173
    [Abstract] [Full Text] [Related]

  • 12. Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies.
    Callemeyn J, Lerut E, de Loor H, Arijs I, Thaunat O, Koenig A, Meas-Yedid V, Olivo-Marin JC, Halloran P, Chang J, Thorrez L, Kuypers D, Sprangers B, Van Lommel L, Schuit F, Essig M, Gwinner W, Anglicheau D, Marquet P, Naesens M.
    J Am Soc Nephrol; 2020 Sep; 31(9):2168-2183. PubMed ID: 32641395
    [Abstract] [Full Text] [Related]

  • 13. De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury.
    Yamamoto T, Watarai Y, Takeda A, Tsujita M, Hiramitsu T, Goto N, Narumi S, Katayama A, Morozumi K, Uchida K, Kobayashi T.
    Transplantation; 2016 Oct; 100(10):2194-202. PubMed ID: 26636737
    [Abstract] [Full Text] [Related]

  • 14. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
    Naciri Bennani H, Daligault M, Noble J, Bardy B, Motte L, Giovannini D, Emprou C, Fiard G, Imerzoukene F, Bourdin A, Masson D, Janbon B, Malvezzi P, Rostaing L, Jouve T.
    J Clin Apher; 2021 Aug; 36(4):584-594. PubMed ID: 33783868
    [Abstract] [Full Text] [Related]

  • 15. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
    Vo AA, Sinha A, Haas M, Choi J, Mirocha J, Kahwaji J, Peng A, Villicana R, Jordan SC.
    Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. One-Year Outcomes of Living Related Kidney Transplant in Patients With Preformed HLA Donor-Specific Antibodies: A Single-Center Experience in Malaysia.
    Jalalonmuhali M, Ng KP, Mohd Shariff NH, Lee YW, Wong AH, Gan CC, Lim SK.
    Transplant Proc; 2020 Jul; 52(6):1718-1722. PubMed ID: 32448671
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients.
    Lee KW, Park JB, Cho CW, Lee N, Yoo H, Kim K, Park H, Kang ES, Huh W, Kim S.
    Ann Transplant; 2017 Mar 28; 22():166-176. PubMed ID: 28348361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.